JPC
ATYR

Jackson Park Capital’s aTyr Pharma ATYR Stock Holding History

Jackson Park Capital’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,714
Closed -$210K – 45
2016
Q3 		$210K Hold
4,714
– – 0.27% 42
2016
Q2 		$183K Buy
+4,714
New +$219K 0.25% 42

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
GHCM
Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

Jackson Park Capital's ATYR Position: Q4 2016 in Review

Jackson Park Capital sold out of aTyr Pharma (ATYR) in Q4 2016, closing a stake of 4,714 shares — an estimated $210K sold.

Jackson Park Capital first reported a position in ATYR in Q2 2016 and held it in 2 quarters. The position peaked at $210K in Q3 2016. 52 funds tracked by Wall St. Rank hold ATYR as of Q4 2016.

  • Jackson Park Capital reported no remaining aTyr Pharma position as of Q4 2016 after selling out during the quarter.
  • Jackson Park Capital sold 4,714 aTyr Pharma shares in Q4 2016, an estimated $210K.
  • Jackson Park Capital first reported a position in aTyr Pharma in Q2 2016 and held it in 2 quarters.
  • Jackson Park Capital's aTyr Pharma position peaked at $210K in Q3 2016.
  • 52 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2016.

Based on Jackson Park Capital's 13F filing for Q4 2016, filed 1 Feb 2017.